Foundayo's 19% Weight Loss Boosts Lilly's Oral GLP-1 Sales Outlook
LLY sits 67% above its 52-week low of $623.78.
Summary
Eli Lilly's oral GLP-1 drug, Foundayo, demonstrated an impressive 19% average weight loss in Phase 2/3 trials. This specific efficacy data reinforces the drug's potential, following its FDA approval on April 1st and earlier positive trial announcements. The strong results are projected to significantly boost Lilly's oral GLP-1 sales, enhancing its competitive position in the lucrative obesity and diabetes market.
At the time of this announcement, LLY was trading at $1,043.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $981B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.